Live Breaking News & Updates on Daniel vaena

Stay informed with the latest breaking news from Daniel vaena on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Daniel vaena and stay connected to the pulse of your community

Experts Discuss Current Standards, Selection, and Uncertainties in Bladder and Renal Cancer Care

Experts delineate the latest developments and lingering questions in bladder and renal cancers, covering pivotal trials, emerging therapies, and optimal management approaches.

Vanderbilt-university , Tennessee , United-states , Germantown , Orrs , University-of-tennessee , American , Nikhil-gopal , Daniel-vaena , Enfortumab-vedotin , Bradleyg-somer , Kathryne-beckermann

Belzutifan Regimens Show Promise in RCC as Frontline IO/TKI Armamentarium Expands

Nikhil A. Gopal, MD, discusses the benefit of belzutifan in addition to effective immunotherapy-based regimens in advanced RCC.

Tennessee , United-states , University-of-tennessee , Nikhila-gopal , Daniel-vaena , University-of-tennessee-health-science-center , Department-of-urology , College-of-medicine , Science-summit , Tennessee-health-science-center ,

Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting

Compugen Announces Updated Data from Phase 1 Study of COM701, First- in-Class Anti-PVRIG, at the ASCO 2021 Annual Meeting
Font : A-A+
Data show ongoing durable responses beyond one year in monotherapy and in combination with Opdivo® in heavily pre-treated patients including one patient with prior progression on Opdivo®
HOLON, Israel, June 8, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, presented updated data from its Phase 1 dose escalation and expansion study of COM701 as a monotherapy, and in a dose escalation combination study with Opdivo® (nivolumab) in an oral presentation at the ASCO 2021 Annual Meeting, being held virtually on June 4-8, 2021. COM701 is a first-in-class investigational therapeutic antibody targeting PVRIG, a novel immune checkpoint discovered computationally by Compugen.

Israel , Tel-aviv , Daniel-vaena , Compugen-ltd , Corporate-communications-compugen-ltd , Compugen , Nasdaq , Exchange-commission , Securities-exchange , Tel-aviv-stock-exchange , John-mullaly-lifesci-advisors , Cancer-center-research-institute